Detailed information for compound 1720330

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 1597.71 | Formula: C73H104F4N18O18
  • H donors: 21 H acceptors: 18 LogP: -3.6 Rotable bonds: 60
    Rule of 5 violations (Lipinski): 4
  • SMILES: NCCCC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)O)CCCNC(=N)N)CC(C)C)CC(C)C)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](Cc1c[nH]c2c1ccc(c2)F)NC(=O)[C@H](NC(=O)[C@@H]([C@H](O)C)N)C)Cc1ccc(cc1)O)C)CC(=O)N)Cc1ccc(cc1)C(F)(F)F)CCC(=O)O
  • InChi: 1S/C73H104F4N18O18/c1-35(2)27-51(65(106)89-49(71(112)113)12-10-26-83-72(81)82)93-66(107)52(28-36(3)4)92-62(103)47(11-8-9-25-78)87-63(104)48(23-24-58(99)100)88-67(108)54(29-40-13-17-43(18-14-40)73(75,76)77)95-69(110)56(33-57(79)98)91-60(101)37(5)85-64(105)53(30-41-15-20-45(97)21-16-41)94-68(109)55(31-42-34-84-50-32-44(74)19-22-46(42)50)90-61(102)38(6)86-70(111)59(80)39(7)96/h13-22,32,34-39,47-49,51-56,59,84,96-97H,8-12,23-31,33,78,80H2,1-7H3,(H2,79,98)(H,85,105)(H,86,111)(H,87,104)(H,88,108)(H,89,106)(H,90,102)(H,91,101)(H,92,103)(H,93,107)(H,94,109)(H,95,110)(H,99,100)(H,112,113)(H4,81,82,83)/t37-,38-,39-,47-,48-,49-,51-,52-,53-,54-,55-,56-,59-/m1/s1
  • InChiKey: IKFSHEISEVJQHA-RMRRZSPQSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens MDM2 proto-oncogene, E3 ubiquitin protein ligase Starlite/ChEMBL References
Homo sapiens MDM4, p53 regulator Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus multilocularis SWI:SNF matrix associated 0.0026 0.5 0.5
Toxoplasma gondii DNA topoisomerase domain-containing protein 0.0026 0.5 0.5
Plasmodium falciparum SWIB/MDM2 domain-containing protein 0.0026 0.5 0.5
Plasmodium vivax SWIB/MDM2 domain-containing protein, putative 0.0026 0.5 0.5
Loa Loa (eye worm) brahma associated protein 0.0026 0.5 0.5
Brugia malayi brahma associated protein 60 kDa 0.0026 0.5 0.5
Schistosoma mansoni hypothetical protein 0.0026 0.5 0.5
Echinococcus granulosus Upstream activation factor subunit UAF30 0.0026 0.5 0.5
Chlamydia trachomatis SWIB complex protein 0.0026 0.5 0.5
Plasmodium falciparum SWIB/MDM2 domain-containing protein 0.0026 0.5 0.5
Echinococcus multilocularis Upstream activation factor subunit UAF30 0.0026 0.5 0.5
Schistosoma mansoni brg-1 associated factor 0.0026 0.5 0.5
Toxoplasma gondii SWIB/MDM2 domain-containing protein 0.0026 0.5 0.5
Echinococcus granulosus SWI:SNF matrix associated 0.0026 0.5 0.5
Onchocerca volvulus 0.0026 0.5 0.5
Echinococcus multilocularis SWI:SNF matrix associated 0.0026 0.5 0.5
Chlamydia trachomatis DNA topoisomerase I 0.0026 0.5 0.5
Brugia malayi SWIB/MDM2 domain containing protein 0.0026 0.5 0.5
Trichomonas vaginalis conserved hypothetical protein 0.0026 0.5 0.5
Plasmodium vivax hypothetical protein, conserved 0.0026 0.5 0.5
Schistosoma mansoni hypothetical protein 0.0026 0.5 0.5
Echinococcus multilocularis SWI:SNF matrix associated 0.0026 0.5 0.5
Loa Loa (eye worm) SWIB/MDM2 domain-containing protein 0.0026 0.5 0.5
Schistosoma mansoni hypothetical protein 0.0026 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
Kd (binding) = 0.22 nM Antagonist activity at MDM2 (residues 25 to 109) assessed as inhibition of binding to immobilized p53 (residues 15 to 29) preincubated for 30 mins by surface plasmon resonance method ChEMBL. 22694121
Kd (binding) = 200 nM Inhibition of MDMX (residues 24 to 108) binding to immobilized p53 (residues 15 to 29) preincubated for 30 mins by surface plasmon resonance method ChEMBL. 22694121

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.